meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population
6
mUC - L1 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
deaths (OS)
mUC - L1 - PDL1 positive
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - PDL1 positive
versus gemcitabine plus platin
durvalumab plus tremelimumab vs. gemcitabine plus platin
1
certainty unassessable
-24%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open